Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori

Gut and Liver

Volumn 6, Issue 4, 2012, Pages 452-456

  Yun, Sang Pil ^a   Seon, Han Gyung ^a   Ok, Chang Soo ^a   Yoo, Kwang Ho ^a   Kang, Min Kyung ^a   Kim, Won Hee ^a   Kwon, Chang Il ^a   Ko, Kwang Hyun ^a   Hwang, Seong Gyu ^a   Park, Pil Won ^a   Hong, Sung Pyo ^a  

^a CHA University   (South Korea)

Author keywords

Eradication; Helicobacter pylori; Rifaximin

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; RIFAXIMIN; TETRACYCLINE;

ADULT; ARTICLE; BITTER TASTE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC DISCOMFORT; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 84868152695     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.4.452     Document Type: Article

References (44)

1. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
2. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 2004;36:243-247.
3. Romano M, Cuomo A. Eradication of Helicobacter pylori: a clinical update. MedGenMed 2004;6:19.
4. McLoughlin RM, O'Morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421-427.
5. Candelli M, Nista EC, Carloni E, et al. Treatment of H. pylori infection: a review. Curr Med Chem 2005;12:375-384.
6. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-1855.
7. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000;32:763-768.
8. Cho DK, Park SY, Kee WJ, et al. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterol 2010;55:368-375.
9. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-726.
10. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003;35:523-528.
11. Pilotto A, Franceschi M, Rassu M, Furlan F, Scagnelli M. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000;95:833-834.
12. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-1499.
13. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity: a review. Chemotherapy 2005;51 Suppl 1:67-72.
14. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-211.
15. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003;35:232-236.
16. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006;24:1469-1474.
17. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340.
18. Kim SY, Jung SW. Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol 2011;58:67-73.
19. Kim JY, Kim N, Park HK, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea. Korean J Gastroenterol 2011;58:74-81.
20. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010;44:536-543.
21. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-1275.
22. Sezikli M, Cetinkaya ZA, Güzelbulut F, et al. Efficacy of the combination of tetracycline, amoxicillin, and lansoprazole in the eradication of Helicobacter pylori in treatment-naive patients and in patients who are not responsive to clarithromycin-based regimens: a pilot study. Gut Liver 2012;6:41-44.
23. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94.
24. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316.
25. Mégraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994;13:184-186.
26. Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995;35:545-549.
27. Pretolani S, Bonvicini F, Brocci E, et al. Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection. Acta Gastroenterol Belg 1993;56:144A.
28. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-1343.
29. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-1312.
30. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633.
31. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;48:19-24.
32. Jung HS, Shim KN, Baik SJ, et al. Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol 2008;51:285-290.
33. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion 2006;73 Suppl 1:129-135.
34. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis 2006;24:195-200.
35. Song JG, Lee SW, Park JY, et al. Trend in the eradication rates of Helicobacter pylori infection in the last 11 years. Korean J Med 2009;76:303-310.
36. Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006;48:156-161.
37. Chung JW, Lee GH, Han JH, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011;58:246-250.
38. Chung WC, Lee KM, Paik CN, et al. Inter-departmental differences in the eradication therapy for Helicobacter pylori infection: a single center study. Korean J Gastroenterol 2009;53:221-227.
39. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170-175.
40. Cho HJ, Bae RC, Lee SH, et al. The trend in the eradication rates of first- and second-line therapy for Helicobacter pylori infection in Daegu and Kyungpook provinces: a single center experience for the most recent 9 years. Korean J Med 2009;76:186-192.
41. Oh JH, Kim TH, Cheung DY, et al. Eradication rates of bismuth-based quadruple therapy as a second-line treatment for Helicobacter pylori infection. Korean J Gastrointest Endosc 2009;39:131-135.
42. Cho EJ, Lee DH, Chun JY, et al. Recent trends in the eradication rates of second-line quadruple 14 therapy for Helicobacter pylori and the clinical factors that potentially affect the treatment outcome. Korean J Gastrointest Endosc 2009;38:14-19.
43. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
44. Lee SK, Lee SW, Park JY, et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter 2011;16:410-414.